Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).

The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.